Skip to main content

Table 3 Audit results regarding administration of treatments (n = 4307)

From: Community Assessment of COPD Health Care (COACH) study: a clinical audit on primary care performance variability in COPD care

Variables Average (Patient level) Inter-center range Inter-regional range
Range P value a Range P value a
Non-pharmacological treatments
 Recommendations about not smoking 1051 (24.4) 0–76.5 <  0.001 6.1–36.4 <  0.001
 Perform some exercise 958 (22.2) 0–84.7 <  0.001 3.2–41.8 <  0.001
 Influenza vaccination administered 2869 (66.6) 34.1–95.2 <  0.001 53.4–73.3 <  0.001
 Pneumococcal vaccination administered 1620 (37.6) 0–82.3 <  0.001 10.8–65.2 <  0.001
Inhaled maintenance therapies
 No inhaled treatment/not available 1446 (33.6) 8.8–54.9 <  0.001 26.5–42.9 <  0.001
 One long-acting bronchodilator 653 (15.2) 0–33.3 <  0.001 11.3–18.9 <  0.001
 LAMA + LABA b 392 (9.1) 0–35.3 <  0.001 6.9–10.0 0.025
 ICS alone 67 (1.6) 0–11.1 0.018 0.6–3.4 0.002
 ICS + one long-acting bronchodilator 804 (18.7) 0–38.2 <  0.001 14.8–25.4 <  0.001
 Triple therapy 945 (21.9) 0–50.0 <  0.001 18.9–24.9 0.002
 ICS-containing regimens 1816 (42.2) 12.5–66.3 <  0.001 38.6–51.1 <  0.001
 Incorrect prescription c 224 (5.2) 0–14.7 <  0.001 3.6–6.9 <  0.001
Oral maintenance therapies
 Roflumilast 58 (1.3) 0–7.7 <  0.001 1.0–1.7 0.693
 Mucolytics 96 (2.2) 0–26.7 <  0.001 0.2–4.0 <  0.001
 Antibiotics 29 (0.7) 0–6,7 <  0.001 0.2–1.3 0.022
 Methylxanthines 97 (2.3) 0–17.6 <  0.001 0.2–6.2 <  0.001
Home-based therapies
 Long-term oxygen therapy 175 (4.1) 0–18.8 <  0.001 2.3–5.4 0.029
 Home mechanical ventilation 35 (0.8) 0–10.0 <  0.001 0.1–1.9 <  0.001
 Nebulized therapy 121 (2.8) 0–22.4 <  0.001 0.1–6.4 <  0.001
  1. Data are expressed as absolute (relative) frequencies in reference to the whole cohort unless otherwise specified
  2. LABA long-active ß2 agonist, LAMA long-acting muscarinic antagonist, ICS inhaled corticosteroids
  3. a Calculated by Chi-squared test or ANOVA to test for variability
  4. b Combined in one single inhaler or not. Only indacaterol-glycopyrronium combination was available in the country at the time of the audit
  5. c Per the protocol, the following scenarios were deemed to represent incorrect prescriptions: GOLD 2017 B-D patients without any medication registered, any case of ICS use alone, and those prescriptions that duplicated drugs in combined or single therapies